From the Editor

Cesarean myomectomy: Safe operation or surgical folly?

Author and Disclosure Information

 

References

A systematic review and meta-analysis reported on the results of 17 studies which included 4,702 women who had a cesarean myomectomy and 1,843 women with cesarean birth without myomectomy.17 The authors of the meta-analysis noted that most reported case series had excluded women with a high risk of bleeding, including women with placenta previa, placenta accreta, coagulation disorders, and a history of multiple myomectomy operations. The investigators reported that, compared with the control women, the women undergoing cesarean myomectomy had a statistically significant but clinically insignificant decrease in mean hemoglobin concentration (-0.27 g/dL), a significant increase in mean operative time (+15 minutes) and a significant increase in the length of hospital stay (+0.36 days). There was an increase in the need for blood transfusion (risk ratio, 1.45; 95% confidence interval, 1.05–1.99), but only 3% of women undergoing cesarean myomectomy received a blood transfusion. There was no significant difference between the two groups in the incidence of postoperative fever. The authors concluded that cesarean myomectomy is a safe procedure when performed by experienced surgeons with appropriate hemostatic techniques.

Techniques to reduce blood loss at the time of cesarean myomectomy

A detailed review of all the available techniques to reduce blood loss at the time of cesarean myomectomy is beyond the scope of this editorial. All gynecologists know that control of uterine blood flow through the uterine artery, infundibulopelvic vessels and internal iliac artery can help to reduce bleeding at the time of myomectomy. Tourniquets, vascular clamps, and artery ligation all have been reported to be useful at the time of cesarean myomectomy. In addition, intravenous infusion of oxytocin and tranexamic acid is often used at the time of cesarean myomectomy. Direct injection of uterotonics, including carbetocin, oxytocin, and vasopressin, into the uterus also has been reported. Cell saver blood salvage technology has been utilized in a limited number of cases of cesarean myomectomy.8,18,19

Medicine is not a static field

Discoveries and new data help guide advances in medical practice. After 6 decades of strict adherence to the advice that myomectomy in pregnancy should be avoided at all costs, including at caesarean delivery, new data indicate that in carefully selected cases cesarean myomectomy is an acceptable operation. ●

Pages

Recommended Reading

Uterine tissue extraction: An update, with a look at tools and techniques
MDedge ObGyn
Miscarriage after myomectomy depends on fibroid number, uterine incisions
MDedge ObGyn
Fibroids: Patient considerations in medical and surgical management
MDedge ObGyn
Is elagolix effective at reducing HMB for women with varying fibroid sizes and types?
MDedge ObGyn
Product update: Neuromodulation device, cystoscopy simplified, hysteroscopy seal, next immunization frontier
MDedge ObGyn
Can a drug FDA approved for endometriosis become a mainstay for nonsurgical treatment of HMB in women with fibroids?
MDedge ObGyn
How effective is elagolix treatment in women with fibroids and HMB?
MDedge ObGyn
New hormonal medical treatment is an important advance for AUB caused by uterine fibroids
MDedge ObGyn
Hysteroscopy and COVID-19: Have recommended techniques changed due to the pandemic?
MDedge ObGyn
Prophylactic antibiotics for myomectomy?
MDedge ObGyn